SpectRx Sets Dates for 2001 First Quarter Results & Conference Call

Apr 26, 2001, 01:00 ET from SpectRx, Inc.

    NORCROSS, Ga., April 26 /PRNewswire/ -- SpectRx, Inc. (Nasdaq:   SPRX)
 announced today that it plans to release first quarter results after the
 market closes on Wednesday May 2, 2001.  In conjunction with this release,
 SpectRx will host a conference call to be broadcast live over the Internet at
 10 a.m. EDT on Thursday May 3, 2001.  The live call and replay can be accessed
 at www.vcall.com .
     SpectRx, a specialty point-of-care medical technology company, develops
 and manufactures non-invasive and minimally invasive diagnostic and monitoring
 systems.  The company employs leading-edge biophotonics, or the use of light
 and spectral energies, to develop painless point-of-care alternatives to
 blood- and tissue-based procedures.  Through internal product development and
 partnerships with major health care companies, SpectRx focuses on key niche
 and large diagnostic markets, primarily oncology, endocrinology and
 neonatology.  The Company's handheld, FDA-cleared BiliChek(TM) (sold
 internationally as BiliCheck(TM)) is the first commercially available non-
 invasive painless monitor for infant jaundice.  Under development are products
 for the non-invasive detection of cervical cancer and Type II diabetes, and a
 consumer device for continuous glucose monitoring.
     For more information, visit SpectRx's web sites at www.spectrx.com and
 www.bilicheck.com , or use Internet Keyword spectrx.
 
     "Safe Harbor" Statement under the Private Securities Litigation Reform Act
 of 1995.  Certain matters and subject areas discussed in this press release
 that are not historical or current facts deal with potential future
 circumstances and developments.  The discussion of such matters and subject
 areas is qualified by the inherent risks and uncertainties surrounding future
 expectations generally and also may materially differ from SpectRx's actual
 future experience involving any of or more of such matters and subject areas.
 Such risks and uncertainties include overall economic trends, successful
 development of new products and regulatory matters as well as those that are
 more fully described from time to time in SpectRx's reports filed with the SEC
 under the heading "Risk Factors", including SpectRx's Annual Report on Form
 10-K for the fiscal year ended December 31, 2000 and in the Forms 10-Q for the
 first, second and third quarters of 2000 filed by SpectRx.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X27482631
 
 

SOURCE SpectRx, Inc.
    NORCROSS, Ga., April 26 /PRNewswire/ -- SpectRx, Inc. (Nasdaq:   SPRX)
 announced today that it plans to release first quarter results after the
 market closes on Wednesday May 2, 2001.  In conjunction with this release,
 SpectRx will host a conference call to be broadcast live over the Internet at
 10 a.m. EDT on Thursday May 3, 2001.  The live call and replay can be accessed
 at www.vcall.com .
     SpectRx, a specialty point-of-care medical technology company, develops
 and manufactures non-invasive and minimally invasive diagnostic and monitoring
 systems.  The company employs leading-edge biophotonics, or the use of light
 and spectral energies, to develop painless point-of-care alternatives to
 blood- and tissue-based procedures.  Through internal product development and
 partnerships with major health care companies, SpectRx focuses on key niche
 and large diagnostic markets, primarily oncology, endocrinology and
 neonatology.  The Company's handheld, FDA-cleared BiliChek(TM) (sold
 internationally as BiliCheck(TM)) is the first commercially available non-
 invasive painless monitor for infant jaundice.  Under development are products
 for the non-invasive detection of cervical cancer and Type II diabetes, and a
 consumer device for continuous glucose monitoring.
     For more information, visit SpectRx's web sites at www.spectrx.com and
 www.bilicheck.com , or use Internet Keyword spectrx.
 
     "Safe Harbor" Statement under the Private Securities Litigation Reform Act
 of 1995.  Certain matters and subject areas discussed in this press release
 that are not historical or current facts deal with potential future
 circumstances and developments.  The discussion of such matters and subject
 areas is qualified by the inherent risks and uncertainties surrounding future
 expectations generally and also may materially differ from SpectRx's actual
 future experience involving any of or more of such matters and subject areas.
 Such risks and uncertainties include overall economic trends, successful
 development of new products and regulatory matters as well as those that are
 more fully described from time to time in SpectRx's reports filed with the SEC
 under the heading "Risk Factors", including SpectRx's Annual Report on Form
 10-K for the fiscal year ended December 31, 2000 and in the Forms 10-Q for the
 first, second and third quarters of 2000 filed by SpectRx.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X27482631
 
 SOURCE  SpectRx, Inc.